BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 16432296)

  • 21. [Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension].
    Tabata T; Ono S; Song C; Noda M; Suzuki S; Tanita T; Fujimura S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Feb; 35(2):160-6. PubMed ID: 9103852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
    Nishimura T; Faul JL; Berry GJ; Vaszar LT; Qiu D; Pearl RG; Kao PN
    Am J Respir Crit Care Med; 2002 Nov; 166(10):1403-8. PubMed ID: 12406854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of triptolide on the development of monocrotaline-induced pulmonary hypertension in pneumonectomized rat].
    Wei L; Liu T; Liu B; Wang XM; Zhao L; Zhou TF
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):806-9. PubMed ID: 17953363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
    Cassis LA; Rippetoe PE; Soltis EE; Painter DJ; Fitz R; Gillespie MN
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1168-72. PubMed ID: 1527721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.
    Prié S; Leung TK; Cernacek P; Ryan JW; Dupuis J
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1312-8. PubMed ID: 9316840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of various doses of monocrotaline administration on the development of pulmonary hypertension and its regression in rats].
    Kakusaka I; Kaneko N; Kiyatake K; Fujita A; Suzuki A; Nakano K; Okada O; Sugita T; Watanabe S; Kuriyama T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jan; 27(1):51-6. PubMed ID: 2501548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension.
    Kanki-Horimoto S; Horimoto H; Mieno S; Kishida K; Watanabe F; Furuya E; Katsumata T
    Circulation; 2006 Jul; 114(1 Suppl):I181-5. PubMed ID: 16820570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of increased pulmonary flow on the expression of endothelial nitric oxide synthase and endothelin-1 in the rat.
    Dai ZK; Tan MS; Chai CY; Chen IJ; Jeng AY; Wu JR
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():289S-293S. PubMed ID: 12193106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
    Wang Y; Zhang XH; Wang HL
    Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of Kv4.2 and Kv4.3 channel gene expression in right ventricular hypertrophy induced by monocrotaline in rat.
    Zhang TT; Cui B; Dai DZ
    Acta Pharmacol Sin; 2004 Feb; 25(2):226-30. PubMed ID: 14769214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of triptolide on the expression of matrix metalloproteinases 2 and 9 in lungs of experimental pulmonary hypertension].
    Wei L; Liu T; Liu B; Wang XM; Zhao L; Zhou TF
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Oct; 9(5):479-83. PubMed ID: 17937863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Zopf DA; das Neves LA; Nikula KJ; Huang J; Senese PB; Gralinski MR
    Eur J Pharmacol; 2011 Nov; 670(1):195-203. PubMed ID: 21914448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KMUP-1 ameliorates monocrotaline-induced pulmonary arterial hypertension through the modulation of Ca2+ sensitization and K+-channel.
    Dai ZK; Cheng YJ; Chung HH; Wu JR; Chen IJ; Wu BN
    Life Sci; 2010 May; 86(19-20):747-55. PubMed ID: 20303989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Lung 3H-thymidine incorporation in monocrotaline (MCT)-treated rats--role of platelet-activating factor (PAF)].
    Ono S; Tanita T; Ashino Y; Noda M; Tabata S; Hoshikawa Y; Ueda S; Nishimura T; Fujimura S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1994 May; 32(5):441-5. PubMed ID: 8084100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
    Ozturk EI; Uma S
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):498-505. PubMed ID: 20729759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats.
    Le Pavec J; Perros F; Eddahibi S; Decante B; Dorfmuller P; Sitbon O; Lebrec D; Humbert M; Mazmanian M; Herve P
    Eur Respir J; 2009 Sep; 34(3):731-9. PubMed ID: 19324959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
    Shen L; Shen J; Pu J; He B
    Cell Biochem Biophys; 2011 Sep; 61(1):23-31. PubMed ID: 21327581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
    Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
    Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.